Dr. Datson has entered into an exclusive contract manufacturing partnership with Ochoa Labs. Dr. Datsons Labs will manufacture on an exclusive basis to the Ochoa Labs requirements of Docetaxel Anhydrous, Irinotecan Hydrochloride, Topotecan Hydrochloride, Semi Synthetic Paclitaxel, Gemcltablne Hydrochloride, Capecitabine, Imatinib Mesylate Gefitinib in finished formulations.
Recently, the company received the proposal to supply the Artemisinin-based combination therapies (ACTs) to the Clinton Health Access Initiative (CHAI), the healthcare project of the Clinton Foundation.
Dr. Datsons Labs is a leading research based integrated pharmaceutical company with established research, manufacturing and marketing capabilities. It is R&D focused, has a multi product portfolio with state of the art manufacturing facilities, and is set to become a marketing conglomerate across the globe.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1693.15 |
| Dr. Reddys Lab | 1221.25 |
| Cipla | 1230.75 |
| Zydus Lifesciences | 939.20 |
| Lupin | 2326.50 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: